AP PSYCHOLOGY (All Sets Combined) Flashcards. Human bodies are programmed to maintain weight. The lateral(hungry) and ventromedial hypothalamus(full) acts to cancel each other out. Our fatty cells have a set- point they want to maintain. Heredity influences set points and therefore, body type also. If weight is lost, food intake is increased and energy expenditure(metabolism) decreases or vice versa. Attention deficit/hyperactivity disorder (ADHD) is a common condition among children and adolescents, and has been diagnosed with increased frequency in. Sensory Calming Quicklist. Center of Development Pediatric Therapies 931-372-2567 Seuss IEP (Author unknown) Ever been to an IEP? Then check out this clever poem about IEP's (to the rhythm of Green Eggs And Ham). FDA prescribing information, side effects and uses. Strattera is indicated for the treatment of Attention- Deficit/Hyperactivity Disorder (ADHD). The efficacy of Strattera Capsules was established in seven clinical trials in outpatients with ADHD: four 6 to 9- week trials in pediatric patients (ages 6 to 1. The symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e. The symptoms must not be better accounted for by another mental disorder. The specific etiology of ADHD is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but also of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the patient and not solely on the presence of the required number of DSM- IV characteristics. For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes, lack of sustained attention, poor listener, failure to follow through on tasks, poor organization, avoids tasks requiring sustained mental effort, loses things, easily distracted, forgetful. For the Hyperactive- Impulsive Type, at least 6 of the following symptoms must have persisted for at least 6 months: fidgeting/squirming, leaving seat, inappropriate running/climbing, difficulty with quiet activities, βon the go,β excessive talking, blurting answers, can't wait turn, intrusive. For a Combined Type diagnosis, both inattentive and hyperactive- impulsive criteria must be met. Strattera is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all patients with this syndrome. Drug treatment is not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential in children and adolescents with this diagnosis and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe drug treatment medication will depend upon the physician's assessment of the chronicity and severity of the patient's symptoms. Dosing of children and adolescents up to 7. Join Us On GFCF Kids . Gluten Free/Casein Free Food List Partial Seizures (Produced by a small area of the brain) Symptoms: 1. Simple (awareness is retained) a. Simple Psychological. Forward: Although this depression treatment by magnesium essay was written originally to address the role of magnesium as a depression treatment, the role of. Introductory Notes: These suggestions were gathered from several sources, including the Take 5 companion book to the Alert Program by Williams and Shellenberger, and. Strattera should be initiated at a total daily dose of approximately 0. No additional benefit has been demonstrated for doses higher than 1. After 2 to 4 additional weeks, the dose may be increased to a maximum of 1. There are no data that support increased effectiveness at higher doses . The benefit of maintaining pediatric patients (ages 6- 1. ADHD on Strattera after achieving a response in a dose range of 1. Patients assigned to Strattera in the maintenance phase were generally continued on the same dose used to achieve a response in the open label phase. The physician who elects to use Strattera for extended periods should periodically reevaluate the long- term usefulness of the drug for the individual patient . For patients with severe HI (Child- Pugh Class C), initial dose and target doses should be reduced to 2. Treatment with an MAOI should not be initiated within 2 weeks after discontinuing Strattera. With other drugs that affect brain monoamine concentrations, there have been reports of serious, sometimes fatal reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) when taken in combination with an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Such reactions may occur when these drugs are given concurrently or in close proximity . Therefore, Strattera should not be taken by patients with pheochromocytoma or a history of pheochromocytoma. Strattera should not be used in patients with severe cardiac or vascular disorders whose condition would be expected to deteriorate if they experience increases in blood pressure or heart rate that could be clinically important (for example, 1. Hg in blood pressure or 2. Pooled analyses of short- term (6 to 1. Strattera in children and adolescents have revealed a greater risk of suicidal ideation early during treatment in those receiving Strattera. There were a total of 1. ADHD and 1 in enuresis) involving over 2. Strattera and 8. 51 receiving placebo). The average risk of suicidal ideation in patients receiving Strattera was 0. There was 1 suicide attempt among these approximately 2. Strattera. No suicides occurred in these trials. All reactions occurred in children 1. All reactions occurred during the first month of treatment. It is unknown whether the risk of suicidal ideation in pediatric patients extends to longer- term use. A similar analysis in adult patients treated with Strattera for either ADHD or major depressive disorder (MDD) did not reveal an increased risk of suicidal ideation or behavior in association with the use of Strattera. All pediatric patients being treated with Strattera should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. The following symptoms have been reported with Strattera: anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania and mania. Although a causal link between the emergence of such symptoms and the emergence of suicidal impulses has not been established, there is a concern that such symptoms may represent precursors to emerging suicidality. Thus, patients being treated with Strattera should be observed for the emergence of such symptoms. Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients who are experiencing emergent suicidality or symptoms that might be precursors to emerging suicidality, especially if these symptoms are severe or abrupt in onset, or were not part of the patient's presenting symptoms. Families and caregivers of pediatric patients being treated with Strattera should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to healthcare providers. Such monitoring should include daily observation by families and caregivers. Postmarketing reports indicate that Strattera can cause severe liver injury. Although no evidence of liver injury was detected in clinical trials of about 6. Strattera use in postmarketing experience. Rare cases of liver failure have also been reported, including a case that resulted in a liver transplant. Because of probable underreporting, it is impossible to provide an accurate estimate of the true incidence of these reactions. Reported cases of liver injury occurred within 1. In one patient, liver injury, manifested by elevated hepatic enzymes up to 4. X ULN and jaundice with bilirubin up to 1. X ULN, recurred upon rechallenge, and was followed by recovery upon drug discontinuation, providing evidence that Strattera likely caused the liver injury. Such reactions may occur several months after therapy is started, but laboratory abnormalities may continue to worsen for several weeks after drug is stopped. The patient described above recovered from his liver injury, and did not require a liver transplant. Strattera should be discontinued in patients with jaundice or laboratory evidence of liver injury, and should not be restarted. Laboratory testing to determine liver enzyme levels should be done upon the first symptom or sign of liver dysfunction (e. Although some serious heart problems alone carry an increased risk of sudden death, atomoxetine generally should not be used in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the noradrenergic effects of atomoxetine. Adults β Sudden deaths, stroke, and myocardial infarction have been reported in adults taking atomoxetine at usual doses for ADHD. Although the role of atomoxetine in these adult cases is also unknown, adults have a greater likelihood than children of having serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems. Consideration should be given to not treating adults with clinically significant cardiac abnormalities. Children, adolescents, or adults who are being considered for treatment with atomoxetine should have a careful history (including assessment for a family history of sudden death or ventricular arrhythmia) and physical exam to assess for the presence of cardiac disease, and should receive further cardiac evaluation if findings suggest such disease (e. Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during atomoxetine treatment should undergo a prompt cardiac evaluation. Strattera should be used with caution in patients whose underlying medical conditions could be worsened by increases in blood pressure or heart rate such as certain patients with hypertension, tachycardia, or cardiovascular or cerebrovascular disease. It should not be used in patients with severe cardiac or vascular disorders whose condition would be expected to deteriorate if they experienced clinically important increases in blood pressure or heart rate .
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
July 2017
Categories |